Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 5;3(1):133.
doi: 10.1038/s43856-023-00363-0.

Impact of individual and environmental factors on dietary or lifestyle interventions to prevent type 2 diabetes development: a systematic review

Collaborators, Affiliations

Impact of individual and environmental factors on dietary or lifestyle interventions to prevent type 2 diabetes development: a systematic review

Dhanasekaran Bodhini et al. Commun Med (Lond). .

Abstract

Background: The variability in the effectiveness of type 2 diabetes (T2D) preventive interventions highlights the potential to identify the factors that determine treatment responses and those that would benefit the most from a given intervention. We conducted a systematic review to synthesize the evidence to support whether sociodemographic, clinical, behavioral, and molecular factors modify the efficacy of dietary or lifestyle interventions to prevent T2D.

Methods: We searched MEDLINE, Embase, and Cochrane databases for studies reporting on the effect of a lifestyle, dietary pattern, or dietary supplement interventions on the incidence of T2D and reporting the results stratified by any effect modifier. We extracted relevant statistical findings and qualitatively synthesized the evidence for each modifier based on the direction of findings reported in available studies. We used the Diabetes Canada Clinical Practice Scale to assess the certainty of the evidence for a given effect modifier.

Results: The 81 publications that met our criteria for inclusion are from 33 unique trials. The evidence is low to very low to attribute variability in intervention effectiveness to individual characteristics such as age, sex, BMI, race/ethnicity, socioeconomic status, baseline behavioral factors, or genetic predisposition.

Conclusions: We report evidence, albeit low certainty, that those with poorer health status, particularly those with prediabetes at baseline, tend to benefit more from T2D prevention strategies compared to healthier counterparts. Our synthesis highlights the need for purposefully designed clinical trials to inform whether individual factors influence the success of T2D prevention strategies.

Plain language summary

Clinical trials to prevent development of type 2 diabetes (T2D) that test dietary and lifestyle interventions have resulted in different results for different study participants. We hypothesized that the differing responses could be because of different personal, social and inherited factors. We searched different databases containing details of published research studies investigating this to look at the effect of these factors on prevention of the development of T2D. We found a small amount of evidence suggesting that those with poorer health, particularly those with a higher amount of sugar in their blood, tend to benefit more from T2D prevention strategies compared to healthier counterparts. Our results suggest that further clinical trials that are designed to examine the effect of personal and social factors on interventions for T2D prevention are needed to better determine the impact of these factors on the success of diet and lifestyle interventions for T2D.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing interests: R.W.M. and P.W.F. are employees of the Novo Nordisk Foundation, a private philanthropic enterprise foundation. The opinions expressed in this article do not necessarily reflect the perspectives of the Novo Nordisk Foundation. V.M. has acted as consultant and speaker and received research or educational grants from Novo Nordisk, MSD, Eli Lilly, Novartis, Boehringer Ingelheim, Lifescan J&J, Sanofi-Aventis, Roche Diagnostics, Abbott, and several Indian pharmaceutical companies, including USV, Dr. Reddy’s Laboratories, and Sun Pharma. None of the other authors have any conflicts of interest to declare.

Figures

Fig. 1
Fig. 1. PRISMA flow diagram.
Stepwise screening stages adapted for selecting the studies of interest using Covidence software. Screening at all stages was done by two independent reviewers, and a third reviewer resolved conflicts.
Fig. 2
Fig. 2. Potential effect modifiers of lifestyle, diet, and diet supplements intervention on the incidence of T2D.
General overview of potential effect modifiers of lifestyle (a), dietary (b), and supplement (c) interventions on the incidence of type 2 diabetes. The Y axes indicate potential effect modifiers, and the X axes illustrate the total number of trial participants included in the studies investigating each modifier. The proportion of gray or white in each bar indicates the number of trial participants included in the studies where there was (gray) or was not (white) an effect by the effect modifier. Caution is warranted because whether an effect modifier did (or did not) have an effect is based on statistical significance from the publication’s summary statistics. It is improbable that the effect modifier strictly did (or did not) have an effect on every participant included in that publication. The number of trials and trial participants are plotted because some trials (e.g., DPP) had multiple studies published using the same participants, so that the participant number would be heavily skewed. There was no instance where the same trial had multiple published studies evaluating the same effect modifier showing different results (e.g., there was no difference between sexes on the PREDIMED trial’s effect on T2D incidence in their primary vs. subgroup studies/publications). The number at the end of each bar represents the number of trials for each potential effect modifier. *indicates an exception for genetics because the effect modifiers (SNPs or GRS) were all uniquely distinct but are presented together under the categories of “SNP” or “GRS” here.

References

    1. Sun H, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022;183:109119. - PMC - PubMed
    1. Tuomi T, et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2014;383:1084–1094. - PubMed
    1. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002;346:393–403. - PMC - PubMed
    1. Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001;344:1343–1350. - PubMed
    1. Pan XR, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–544. - PubMed